抗IgE抗体在支气管哮喘中的应用  

The application of anti-IgE antibody in the treatment of bronchial asthma

作　　者：安霞[1] 金美玲[1] 

机构地区：[1]复旦大学附属中山医院呼吸科,上海200032

出　　处：《世界临床药物》2010年第1期6-10,共5页World Clinical Drug

基　　金：上海市重点学科建设项目(项目编号:B115)

摘　　要：IgE在支气管哮喘发病中起着关键作用。奥马珠单抗(omalizumab)是重组人源化抗IgE单克隆抗体,其与游离IgE结合可显著降低游离IgE水平。通过下调嗜碱性粒细胞、肥大细胞和树突状细胞上的IgE高亲和力受体,可有效防止炎症介质的释放,进而阻止哮喘的发生和进展。多项临床研究证实,奥马珠单抗可明显改善哮喘症状,减少哮喘急性发作,减少口服或吸入型糖皮质激素用量,改善哮喘患者的生活质量。其耐受性良好,使用安全、不良反应发生率低,是临床哮喘治疗的新策略。本文综述相关领域的研究近况。Immunoglobulin E （IgE）plays a key role in pathophysiology of bronchial asthma. Omalizumab is a recombinant anti-IgE monoclonal antibody, which combines with free IgE to significantly lower free IgE levels. By downregulating the expression of high affinity receptor （Fc ε RI）on basophil, mast cells and dentritic cells, omalizumab can inhibit the release of inflammatory mediators and then slower the progress of asthma. A number of clinical trials have demonstrated that omalizumab can improve the symptoms of asthma effectively, reduce acute asthma attacks and lower oral or inhaled corticosteroids dosage as well. Therefore, it can improve life quality of asthma patients. Omalizumab can be well tolerated, safer and less adverse reactions. It is a new approach for asthma treatment. This review summarizes the developments in this area to date with 27 references.

关 键 词：IGE 单克隆抗体 奥马珠单抗 支气管哮喘 

分 类 号：R562.25[医药卫生—呼吸系统] R974[医药卫生—内科学]